📄 medicine

Combined Enterococcus faecium SF68®–Butyrate–Folate Supplementation Restores Intestinal Barrier Integrity and Epithelial Metabolic Function in Experimental DSS-Induced Colitis

This study demonstrates that a combined supplementation of *Enterococcus faecium* SF68®, butyrate, and folate effectively restores intestinal barrier integrity, reduces inflammation, and recovers epithelial metabolic function in experimental colitis, showing superior efficacy to SF68® alone and highlighting its potential as a promising adjunctive therapy for inflammatory bowel disease.

Original authors: Clelia Di Salvo, Giulia Valdiserra, Letizia Campigli, Vanessa D’Antongiovanni, Nunzia Bernardini, Lorenzo Flori, Lara Testai, Laura Benvenuti, Carolina Pellegrini, Matteo Fornai, Luca Antonioli

Published 2026-08-05

📖 4 min read☕ Coffee break read

CC BY 4.0

Original authors: Clelia Di Salvo, Giulia Valdiserra, Letizia Campigli, Vanessa D’Antongiovanni, Nunzia Bernardini, Lorenzo Flori, Lara Testai, Laura Benvenuti, Carolina Pellegrini, Matteo Fornai, Luca Antonioli

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your gut as a bustling, high-tech city. The residents are your cells, and the city walls are a tight, protective barrier made of special "sealant" proteins that keep the outside world from crashing in. In a healthy city, this barrier is strong, and the residents have a favorite fuel source called butyrate, which they burn in their power plants (mitochondria) to keep the lights on and the city running smoothly. But sometimes, this city gets attacked. In a condition called Inflammatory Bowel Disease (IBD), the walls start to crumble, the sealants break, and the power plants sputter. The city becomes chaotic, inflamed, and unable to use its fuel. While doctors have tools to calm the fires (inflammation), they often struggle to fix the broken walls or restart the power plants, leaving the city vulnerable to future attacks. Scientists are always looking for a "super-crew" that can do more than just put out fires—they want a team that can rebuild the walls and restore the energy grid all at once.

This is exactly what a team of researchers from the University of Pisa and other institutions set out to test. They wondered if a specific "three-person team" could save the gut city better than any single member working alone. The team consisted of a helpful bacterium called Enterococcus faecium SF68® (let's call him "SF68"), a fuel molecule called butyrate, and a vitamin called folate. They tested this combo in a lab experiment using mice with a gut condition that mimics human colitis. They tried two different strategies: a "Preventive Protocol" (giving the team before the attack started) and a "Curative Protocol" (giving the team after the city was already under siege).

The results were a mix of "good news" and "great news," depending on when they started the treatment. When they tried to stop the attack before it happened, the combo team was very good at calming the inflammation and fixing the city walls, but it didn't stop the overall chaos (the Disease Activity Index) from getting worse. However, when they used the team to treat mice that were already sick, the results were impressive. The combo team significantly reduced the disease severity, something the single bacterium (SF68) couldn't do on its own.

Here is where the magic really happened. The researchers found that while the single bacterium helped a little, the full combo team was the only one that could truly restore the city's "metabolic engine." In the sick mice, the power plants (mitochondria) were broken, and the fuel transporters (the trucks that bring butyrate to the cells) were missing. The combo team fixed the power plants, making them work again, and even added a new type of fuel transporter (MCT4) that the single bacterium couldn't create. It's as if the combo team didn't just patch the holes in the wall; they also rebuilt the power grid and brought in new delivery trucks to ensure the city had the energy it needed to heal itself.

The study suggests that this three-part mixture is a powerful "multi-tool" for gut health. It doesn't just fight the fire; it repairs the damage and restores the city's ability to generate its own energy. While the researchers note that this was a mouse study and more work is needed to see if it works exactly the same way in humans, the findings suggest that combining a probiotic with specific nutrients might be a smarter way to treat gut diseases than using just one ingredient. It's a promising step toward a future where we can help our gut cities not just survive an attack, but thrive again.

Technical Summary: Combined Enterococcus faecium SF68®–Butyrate–Folate Supplementation in Experimental Colitis

Problem Statement
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease, are characterized by a triad of dysbiosis, intestinal epithelial barrier (IEB) dysfunction, and impaired epithelial metabolism. Current therapeutic strategies primarily target inflammation but often fail to restore long-term homeostasis or prevent relapse, as they do not adequately address persistent barrier defects or metabolic impairments. Specifically, IBD is associated with a loss of butyrate-utilizing bacteria, downregulation of short-chain fatty acid (SCFA) transporters, and mitochondrial dysfunction in colonocytes. While probiotics and metabolites like butyrate show promise individually, their clinical efficacy is inconsistent, likely because they target only isolated aspects of the pathophysiology. There is a need for multi-target strategies that simultaneously address inflammation, barrier integrity, and epithelial metabolic competence.

Methodology
The study utilized a Dextran Sulfate Sodium (DSS)-induced colitis model in C57BL/6 male mice to evaluate a novel combined formulation containing Enterococcus faecium SF68® (SF68), butyrate, and folate. The research employed two distinct experimental protocols:

Preventive Protocol: Mice received the mixture (SF68: $10^8$ CFU/mouse/day, butyrate: 0.6 mg/kg, folate: 0.9 µg/mouse) via oral gavage starting 7 days prior to DSS administration and continuing until day 14. DSS (2.5%) was administered for 7 days.
Curative Protocol: The mixture was administered starting on day 3 of a 5-day DSS treatment, continuing until day 14.

A comparator group received a commercially available combination of Bifidobacterium, butyrate, and fructo-oligosaccharides. Control groups included untreated healthy mice and DSS-only mice.

Key Assessments
The study evaluated efficacy across three domains:

Disease Activity: Disease Activity Index (DAI), colon length, and spleen weight.
Inflammation and Barrier Function: Colonic cytokine levels (TNF, IL-1β, IL-6, IL-10), plasma lipopolysaccharide-binding protein (LBP) as a permeability marker, and Western blot analysis of tight junction proteins (ZO-1, occludin, claudin-1).
Metabolic Function: Expression of SCFA transporters (SMCT1, MCT1, MCT4) and citrate synthase activity as a marker of mitochondrial oxidative metabolism.

Key Results

Anti-inflammatory Effects: In the preventive protocol, the mixture significantly reduced colonic TNF levels and uniquely normalized IL-10 levels, outperforming SF68 alone. In the curative protocol, only the mixture significantly reduced TNF levels; SF68 alone lost its efficacy in this setting.
Barrier Integrity: The mixture demonstrated superior efficacy in restoring IEB integrity compared to SF68 alone. In the preventive setting, it reduced plasma LBP and increased ZO-1 and occludin expression. In the curative setting, it reduced LBP, increased occludin, and uniquely restored claudin-1 expression. The comparator formulation showed no significant beneficial effects on these parameters.
Metabolic Restoration: The mixture uniquely upregulated MCT4 expression in both protocols, whereas SF68 alone did not. Furthermore, while DSS significantly reduced citrate synthase activity (indicating mitochondrial dysfunction), only the combined formulation significantly restored this activity in the preventive protocol. SF68 alone failed to restore mitochondrial function.

Significance and Claims
The paper claims that the combination of Enterococcus faecium SF68®, butyrate, and folate provides broader protective effects than probiotic therapy alone by simultaneously targeting inflammation, intestinal barrier dysfunction, and metabolic impairment. The authors posit that the formulation's ability to restore epithelial metabolic competence—evidenced by the recovery of SCFA transporter expression (specifically MCT4) and mitochondrial oxidative metabolism (citrate synthase activity)—is a distinctive feature that differentiates it from single-component interventions.

The study concludes that this multi-target strategy represents a promising adjunctive approach to current IBD therapies. By addressing the interplay between immune responses, microbiota-derived metabolite utilization, and epithelial energy production, the formulation may facilitate the recovery of barrier integrity and intestinal homeostasis, potentially offering a strategy to promote durable mucosal recovery and reduce disease relapse. The authors acknowledge limitations, including the use of a UC-specific model (DSS) and the lack of direct microbiota composition analysis, suggesting that further investigation is warranted to confirm these mechanisms in human contexts.

Technical Summary: Combined Enterococcus faecium SF68®–Butyrate–Folate Supplementation in Experimental Colitis

More like this